GERON CORP amended First Amendment to Loan Agreement with BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership valued at Extended outside date for Tranche B and Tranche C loan availability from December 31, 2025 to July 3 (effective 2026-01-05).
“On January 5, 2026, Geron Corporation ("we" or the "Company") entered into that certain first amendment to loan agreement (the "First Amendment Agreement") with BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership (each, a "Lender"), which are investment funds managed by Pharmakon Advisors, LP, and BioPharma Credit PLC, as collateral agent (the "Agent"), which amends the terms of that certain Loan Agreement, dated as of November 1, 2024 (the "Loan Agreement", and as amended by the First Amendment Agreement, the "Amended Loan Agreement), by and among the Company, the Lenders and the Agent.”
Restructurings & Charges
GERON CORP announced a restructuring with charges of approximately $18 million affecting the entire company (approximately one-third of its current approximately 260 employees).
“affected employees on December 16, 2025, and expects the RIF to be substantially complete in the first quarter of 2026. The Company estimates that it will incur approximately $18 million in restructuring and restructuring-related charges, consisting primarily of one-time employee severance payments, healthcare and related benefits, and other employee-related”
Elizabeth G. O'Farrell was appointed as Chair of the Board at GERON CORP.
“In addition, effective March 10, 2025, Ms. Elizabeth G. O’Farrell, currently the Lead Independent Director of the Board, was appointed Chair of the Board.”
Dawn C. Bir was appointed as Interim President and Chief Executive Officer at GERON CORP.
“Also, effective March 10, 2025, Dawn C. Bir, a current member of the Board, was appointed as the Interim President and Chief Executive Officer of Geron”
John A. Scarlett resigned as President, Chief Executive Officer and Chairman at GERON CORP.
“Effective March 10, 2025, the service of John A. Scarlett, M.D. as the President, Chief Executive Officer and Chairman of the Board of Directors (the “Board”) of Geron Corporation (the “Company” or “Geron”) concluded and, in connection therewith, Dr. Scarlett resigned from the Board.”
Elizabeth G. O'Farrell was appointed as Chair of the Board at GERON CORP.
“In addition, effective March 10, 2025, Ms. Elizabeth G. O'Farrell, currently the Lead Independent Director of the Board, was appointed Chair of the Board.”
Dawn C. Bir was appointed as Interim President and Chief Executive Officer at GERON CORP.
“Also, effective March 10, 2025, Dawn C. Bir, a current member of the Board, was appointed as the Interim President and Chief Executive Officer of Geron to serve in such capacity while the Company conducts a search for a permanent Chief Executive Officer.”
Shareholder Votes
GERON CORP shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2024 at the 2024-05-09 meeting.
“The selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified based upon the following votes: Votes For Votes Against Abstentions Broker Non-Votes 420,096,104 3,227,292 691,320 N/A”
Shareholder Votes
GERON CORP shareholders approved Non-binding advisory vote to approve named executive officer compensation at the 2024-05-09 meeting.
“The non-binding advisory vote to approve the compensation of the Company’s named executive officers as disclosed in the 2024 Proxy Statement was approved based upon the following votes: Votes For Votes Against Abstentions Broker Non-Votes 272,059,071 8,999,145 1,941,720 141,014,780”
Shareholder Votes
GERON CORP shareholders approved Election of three Class I directors at the 2024-05-09 meeting.
“Each of the three (3) nominees to hold office as Class I members of the Board of Directors to serve for a three-year term expiring at the Company’s 2027 annual meeting of stockholders were elected based upon the following votes: Name of Director Nominee Votes In Favor Votes Withheld Broker Non-Votes John F. McDonald 277,269,957 5,729,979 141,014,780 John A. Scarlett, M.D. Robert J. Spiegel, M.D., FACP 275,707,115 243,088,760 7,292,821 39,911,176 141,014,780 141,014,780”
Material Agreements
GERON CORP entered into Underwriting Agreement with Cowen and Company, LLC and Stifel, Nicolaus & Company, Incorporated valued at approximately $150.0 million (effective 2024-03-19).
“On March 19, 2024, Geron Corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cowen and Company, LLC and Stifel, Nicolaus & Company, Incorporated, as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale (the “Offering”) of 41,999,998 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and pre-funded warrants to purchase 8,002,668 shares of Common Stock (the “Pre-Funded Warrants”).”
Earnings Releases
GERON CORP reported the fourth quarter and full year 2023 results: revenue $23,000 and $237,000, respectively.
“loan facility, will be sufficient to fund its projected operating expenses into the third quarter of 2025. Revenues for the three and twelve months ended December 31, 2023, were $23,000 and $237,000, respectively, compared to $103,000 and $596,000 for the comparable 2022 periods. Revenues in both years primarily reflect estimated royalties from sales of”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.